عرض بسيط للتسجيلة

المؤلفSaid Suliman, Ammar
المؤلفKhoder, Mouhamad
المؤلفTolaymat, Ibrahim
المؤلفWebster, Matt
المؤلفAlany, Raid G.
المؤلفWang, Weiguang
المؤلفElhissi, Abdelbary
المؤلفNajlah, Mohammad
تاريخ الإتاحة2023-02-28T10:10:25Z
تاريخ النشر2021
اسم المنشورPharmaceutics
المصدرScopus
معرّف المصادر الموحدhttp://dx.doi.org/10.3390/pharmaceutics13010084
معرّف المصادر الموحدhttp://hdl.handle.net/10576/40529
الملخصDiethyldithiocarbamate Copper II (DDC-Cu) has shown potent anticancer activity against a wide range of cancer cells, but further investigations are hindered by its practical insolubility in water. In this study, inclusion complexes of DDC-Cu with hydroxypropyl beta-cyclodextrin (HP) or sulfobutyl ether beta-cyclodextrin (SBE) were prepared and investigated as an approach to enhance the apparent solubility of DDC-Cu. Formulations were prepared by simple mixing of DDC-Cu with both cyclodextrin (CDs) at room temperature. Phase solubility assessments of the resulting solutions were performed. DDC-Cu CD solutions were freeze-dried for further characterisations by DSC, thermogravimetric analysis (TGA) and FT-IR. Stability and cytotoxicity studies were also performed to investigate the maintenance of DDC-Cu anticancer activity. The phase solubility profile deviated positively from the linearity (Ap type) showing significant solubility enhancement of the DDC-Cu in both CD solutions (approximately 4 mg/mL at 20% w/w CD solutions). The DSC and TGA analysis confirmed the solid solution status of DDC-Cu in CD. The resulting solutions of DDC-Cu were stable for 28 days and conveyed the anticancer activity of DDC-Cu on chemoresistant triple negative breast cancer cell lines, with IC50 values less than 200 nM. Overall, cyclodextrin DDC-Cu complexes offer a great potential for anticancer applications, as evidenced by their very positive effects against chemoresistant triple negative breast cancer cells.
راعي المشروعFunding: This research is funded by NPRP grant (NPRP9-337-3-069) from the Qatar National Funding: This research is funded by NPRP grant (NPRP9-337-3-069) from the Qatar National Re-Research Fund (a member of Qatar Foundation). The findings herein reflect the work, and are solely search Fund (a member of Qatar Foundation). The findings herein reflect the work, and are solely the responsibility, of the authors. the responsibility, of the authors.
اللغةen
الناشرMDPI AG
الموضوعBeta-cyclodextrin
Chemoresistance
Diethyldithiocarbamate copper II
Solubility
Triple negative breast cancer
العنوانCyclodextrin diethyldithiocarbamate copper ii inclusion complexes: A promising chemotherapeutic delivery system against chemoresistant triple negative breast cancer cell lines
النوعArticle
الصفحات12-Jan
رقم العدد1
رقم المجلد13
dc.accessType Open Access


الملفات في هذه التسجيلة

Thumbnail

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة